Literature DB >> 10565597

Lupus anticoagulant induced by the combination of valproate and lamotrigine.

A Echaniz-Laguna1, A Thiriaux, I Ruolt-Olivesi, C Marescaux, E Hirsch.   

Abstract

A 5-year-old boy with generalized absence seizures was treated with valproate (VPA), 30 mg/kg/day. One month after VPA introduction, routine examination showed moderate reduction in fibrinogen and prolonged partial thromboplastin time (PTT). The search for lupus anticoagulant (LAC) was negative. After 10 months of VPA treatment, seizures persisted, and lamotrigine (LTG), 2 mg/kg/day, was progressively given with VPA. Seizures disappeared, but PTT was more prolonged than before LTG introduction. The search for LAC was positive, and enzyme-linked immunosorbent assays (ELISAs) for immunoglobulin G (IgG) anticardiolipid antibodies were positive. Serum autoantibody screen and rheumatoid factor were negative; serum complement was normal. LAC eventually disappeared with VPA discontinuation. We believe that LTG may have exacerbated an initially mild immune response induced by VPA without clinical evidence of systemic disease. We therefore suggest that careful surveillance for LAC and systemic disease should be instituted when VPA is used with LTG.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10565597     DOI: 10.1111/j.1528-1157.1999.tb02054.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  3 in total

Review 1.  Treatment of typical absence seizures and related epileptic syndromes.

Authors:  C P Panayiotopoulos
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 2.  The safety and tolerability of newer antiepileptic drugs in children and adolescents.

Authors:  Dean P Sarco; Blaise F D Bourgeois
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

3.  Galactorrhea associated with juvenile systemic lupus erythematosus: a review of the role of prolactin.

Authors:  Tova Ronis; Ciarán M Duffy; Karen N Watanabe Duffy
Journal:  Pediatr Rheumatol Online J       Date:  2009-10-23       Impact factor: 3.054

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.